novo nordisk wegovy - Search News

News

Novo Nordisk, Wegovy

Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly ,

Al Jazeera on MSN · 20h

Wegovy maker Novo Nordisk warns of layoffs as competition grows

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be unavoidable as competition heats up against its blockbuster obesity drug Wegovy amid rising pressure from rival Eli Lilly.

The Wall Street Journal on MSN · 1d

Novo Nordisk’s Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

Novo Nordisk said second-quarter sales of its blockbuster Wegovy weight-loss drug soared 67% on year, despite waves of U.S. patients using generic unbranded versions of the drug.The Danish company last week slashed full-year guidance,

3h

Novo Nordisk: The Market Has Lost Its Mind

While Novo Nordisk has gotten a lot of attention for its obesity/weight-loss drug Wegovy in recent years, Novo Nordisk is ...

1d

Novo Nordisk, TSMC, Glencore: Stocks Around the World in Focus

The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...

18h

Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

17h

Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

1don MSN

Why Novo Nordisk Stock Is Down Again Today

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

1d

Ozempic Maker Novo Nordisk Terminates Multiple Pipeline Programs, Faces Investor Lawsuit Over GLP-1 Market Misrepresentation

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Makers of Wegovy, Zepbound face competition from compounding pharmacies

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

Stocktwits on MSN2d

Novo Nordisk Downgraded By UBS Over Uncertain Outlook For Wegovy, But Retail Prefers To Look At The Sunny Side

NYSE-listed shares of Danish drugmaker Novo Nordisk (NVO) fell about 3% on Tuesday morning after brokerage UBS downgraded the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results